Breast cancer cells treated with etomoxir to inhibit CPT1A resulted in cell death, while in vivo, mutant KRAS lung tumours were dependent on ACSL3-dependent FAO for tumour initiation and progression [36, 37]. Here, CPT1A is linked to breast carcinoma.